Skip to main content

Table 3 Frequency of adverse drug reactions of grade 3/4 severity (highest NCI CTC grade per category and patient)

From: Trastuzumab in advanced breast cancer – a decade of experience in Germany

Adverse event/organ system Patients with NCI CTC grade [n (%)]
T* T + CT** T + HT*** Total
Hematological     
 Hemoglobin decreased - 13 (1%) - 13 (1%)
 WBC decreased 1 (0%) 57 (4%) - 58 (3%)
 Granulocytes decreased 1 (0%) 16 (1%) 1 (0%) 18 (1%)
Non-hematological     
 Dyspnea 1 (0%) 18 (1%) 1 (0%) 20 (1%)
 Pain 2 (1%) 16 (1%) 3 (1%) 21 (1%)
  1. *trastuzumab monotherapy, **trastuzumab plus chemotherapy, ***trastuzumab plus endocrine therapy only.
  2. NCI CTC: National Cancer Institute Common Toxicity Criteria; WBC: white blood cells.